Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the ...

Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors. The ...

Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...

ArgenTag joins PacBio to enable instrument-free single-cell kits to support long-read isoform sequencing at single-cell ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection.

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

In a new study, an aging clock has revealed neuron-specific aging, as well as potentially neuroprotective compounds.

From molecular chaperones to mitochondrial failure, discover how heat reshapes the human transcriptome and drives the biological cascade that links rising temperatures to organ injury and public ...

This study reports an important and novel finding that TENT5A, an enzyme involved in fine-tuning poly(A) tail length on selected mRNAs, is required for proper enamel mineralization in mice. The ...

A new study reveals that the twin enzymes MNK1 and MNK2 play distinct roles in the brain, with one governing memory and the other social behavior.

Tempus AI Inc. TEM shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence ...

Daphne O. Martschenko and Sam Trejo both want to make the world a better, fairer, more equitable place. But they disagree on ...